201 – 300 of 327
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2008
-
Mark
Value added: increasing the power to assess treatment outcome in joint haemorrhages
(
- Contribution to journal › Article
-
Mark
Effects of pentoxifylline and its metabolites on platelet aggregation in whole blood from healthy humans.
(
- Contribution to journal › Article
-
Mark
VWD type 3 - historical review and contemporary treatment dilemmas
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.111-111(
- Contribution to journal › Published meeting abstract
-
Mark
Blödningstidsbestämning har spelat ut sin roll. Otillförlitlig metod som inte längre bör användas i rutinsjukvården
(
- Contribution to journal › Scientific review
- 2007
-
Mark
The APC-PCI complex concentration predicts outcome of aortic surgery.
(
- Contribution to journal › Article
-
Mark
A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor.
(
- Contribution to journal › Article
-
Mark
Erik von Willebrand.
(
- Contribution to journal › Article
-
Mark
In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
(
- Contribution to journal › Article
-
Mark
Gadolinium Contrast Agent is of Limited Value for Magnetic Resonance Imaging Assessment of Synovial Hypertrophy in Hemophiliacs.
(
- Contribution to journal › Article
-
Mark
VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice.
(
- Contribution to journal › Article
-
Mark
Human Plasma von Willebrand Factor/Factor VIII Complex (Haemate((R)) P/Humate-P((R))) in von Willebrand Disease and Haemophilia A: A Viewpoint by Eric Berntorp.
(
- Contribution to journal › Letter
-
Mark
Von Willebrand: The scientist, the disease, the factor, and the treatment
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation
(
- Contribution to journal › Article
-
Mark
A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors
(
- Contribution to journal › Article
-
Mark
Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin (R)): a prospective study of 50 patients
(
- Contribution to journal › Article
-
Mark
Delays in maturation among adolescents with hemophilia and a history of inhibitors
(
- Contribution to journal › Article
- 2006
-
Mark
Options for treating acute bleeds in addition to bypassing agents: extracorporeal immunoadsorption, FVIII/FIX, desmopressin and antifibrinolytics.
(
- Contribution to journal › Article
-
Mark
Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A
(
- Contribution to journal › Article
-
Mark
Polymorphisms in the IL-10 but not in the IL-1{beta} and IL-4 genes are associated with inhibitor development in patients with hemophilia A.
(
- Contribution to journal › Article
-
Mark
Von Willebrand's disease: clinical management
(
- Contribution to journal › Article
-
Mark
Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A.
(
- Contribution to journal › Article
-
Mark
The 80th anniversary of von Willebrand's disease: history, management and research
(
- Contribution to journal › Scientific review
-
Mark
The von Willebrand Disease Prophylaxis Network (vWD PN): Exploring a treatment concept.
(
- Contribution to journal › Article
-
Mark
Pharmacoeconomics of factor dosing in the haemophilia population.
(
- Contribution to journal › Article
-
Mark
New Approaches to Using FEIBA in the Treatment of Inhibitor Patients.
(
- Contribution to journal › Article
-
Mark
Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3.
(
- Contribution to journal › Article
-
Mark
The next generation of hemophilia treatment specialists
(
- Contribution to journal › Article
-
Mark
Liposuction in Dercum's disease.
2006) p.516-518(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
The need for prophylaxis in von Willebrand's disease and other coagulation disorders
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Inhibitor treatment in haemophilas A and B: Summary statement for the 2006 International Consensus Conference
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
The von Willebrand disease prophylaxis network: exploring a treatment concept.
(
- Contribution to journal › Article
- 2005
-
Mark
Long-term prophylaxis in von Willebrand disease
(
- Contribution to journal › Article
-
Mark
Protein C levels can be forecasted by global haemostatic tests in critically ill patients and predict long-term survival.
(
- Contribution to journal › Article
-
Mark
Haemophilia Inhibitor Genetics Study - evaluation of a model for studies of complex diseases using linkage and association methods.
(
- Contribution to journal › Letter
-
Mark
Cost effectiveness of haemophilia treatment: a cross-national assessment.
(
- Contribution to journal › Article
-
Mark
The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A.
(
- Contribution to journal › Article
-
Mark
Risk factors for venous thrombosis in Swedish children and adolescents.
(
- Contribution to journal › Article
-
Mark
Protein Z and protein Z-dependent protease inhibitor - Determinants of levels and risk of venous thrombosis
(
- Contribution to journal › Article
-
Mark
Pharmacokinetic studies on Wilfactin((R)), a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods
(
- Contribution to journal › Article
- 2004
-
Mark
Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study
(
- Contribution to journal › Article
-
Mark
Willingness to pay for on-demand and prophylactic treatment for severe haemophilia in Sweden.
(
- Contribution to journal › Article
-
Mark
Costs of on-demand and prophylactic treatment for severe haemophilia in Norway and Sweden.
(
- Contribution to journal › Article
-
Mark
Elective orthopedic surgery for hemophilia patients with inhibitors: New opportunities
(
- Contribution to journal › Article
-
Mark
Economic evaluation: what are we looking for and how do we get there?
(
- Contribution to journal › Article
-
Mark
A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia
(
- Contribution to journal › Article
-
Mark
Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A
(
- Contribution to journal › Article
- 2003
-
Mark
On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome.
(
- Contribution to journal › Article
-
Mark
Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay
(
- Contribution to journal › Article
-
Mark
Prophylactic therapy for haemophilia: early experience.
(
- Contribution to journal › Article
-
Mark
Elective orthopaedic surgery for inhibitor patients.
(
- Contribution to journal › Article
-
Mark
Experience with a new percutaneous port system, Percuseal(R), for intravenous injection in patients with haemophilia, von Willebrand disease and severe alpha1-antitrypsin deficiency.
(
- Contribution to journal › Article
-
Mark
Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro.
(
- Contribution to journal › Article
-
Mark
Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations: is it of clinical importance?
(
- Contribution to journal › Article
-
Mark
A Healthy Hemophilic Patient without Arthropathy: From Concept to Clinical Reality.
(
- Contribution to journal › Article
-
Mark
Risk of haemorrhagic stroke in patients with oral anticoagulation compared with the general population
(
- Contribution to journal › Article
-
Mark
Tailored pharmacokinetic dosing allows self-administration and reduces the cost of IV augmentation therapy with human alpha(1)-antitrypsin.
(
- Contribution to journal › Article
-
Mark
Limited protective effect of the CCR5 Delta 32/CCR5 Delta 32 genotype on human immunodeficiency virus infection incidence in a cohort of patients with hemophilia and selection for genotypic X4 virus
(
- Contribution to journal › Article
-
Mark
Monitoring the bioavailability of FEIBA with a thrombin generation assay
(
- Contribution to journal › Article
-
Mark
The pharmacokinetics of clotting factor therapy.
(
- Contribution to journal › Article
-
Mark
Consensus perspectives on prophylactic therapy for haemophilia: summary statement.
(
- Contribution to journal › Letter
- 2002
-
Mark
The prognostic value of global haemostatic tests in the intensive care unit setting.
(
- Contribution to journal › Article
-
Mark
Clinical outcomes and resource utilization associated with haemophilia care in Europe
(
- Contribution to journal › Article
-
Mark
Antibodies to factor VIIa in patients with haemophilia and high-responding inhibitors.
(
- Contribution to journal › Article
-
Mark
Unresolved issues in prophylaxis
(
- Contribution to journal › Article
-
Mark
Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen
(
- Contribution to journal › Article
-
Mark
Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients
(
- Contribution to journal › Article
-
Mark
Progress in haemophilic care: ethical issues.
(
- Contribution to journal › Article
- 2001
-
Mark
Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis
(
- Contribution to journal › Article
-
Mark
An approach to study the viral safety of plasma-derived products in previously treated, non-infected patients
(
- Contribution to journal › Article
-
Mark
Clinical spectrum of hepatitis C-related liver disease and response to treatment with interferon and ribavirin in haemophilia or von Willebrand disease
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction: recombinant vs. human-derived product
(
- Contribution to journal › Article
-
Mark
The concern of viral safety in the treatment of hemophilia
(
- Contribution to journal › Article
-
Mark
Hormone replacement therapy in healthy postmenopausal women: a randomized, placebo-controlled study of effects on coagulation and fibrinolytic factors
(
- Contribution to journal › Article
-
Mark
No increased risk of venous thrombosis in women taking tranexamic acid
(
- Contribution to journal › Letter
-
Mark
Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia
(
- Contribution to journal › Scientific review
-
Mark
Byte från Prothromplex till Beriplex P/N som akut antidot mot warfarin
(
- Contribution to journal › Article
-
Mark
The clinical importance of correctly diagnosing venous thrombosis
(
- Contribution to journal › Article
-
Mark
Therapeutic choices for patients with hemophilia and high-titer inhibitors
(
- Contribution to journal › Article
-
Mark
Anti- and procoagulant activities in factor VII-deficient subjects
(
- Contribution to journal › Article
-
Mark
The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients
(
- Contribution to journal › Article
-
Mark
Symposium in memory of Professor Inga Marie Nilsson
(
- Contribution to journal › Published meeting abstract
- 2000
-
Mark
Effect kinetics of desmopressin-induced platelet retention in healthy volunteers treated with aspirin or placebo
(
- Contribution to journal › Article
-
Mark
Correlation between different intensities of anti-vitamin K treatment and coagulation parameters
(
- Contribution to journal › Article
-
Mark
NovoSeven in warfarin-treated patients
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction and the treatment of hemophilia. Malmo protocol update
(
- Contribution to journal › Article
-
Mark
The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies
(
- Contribution to journal › Article
-
Mark
Impact, diagnosis and treatment of von Willebrand disease
(
- Contribution to journal › Article
-
Mark
Använd hela "analyspaketet" vid utredning av trombospatienten! Och glöm inte släktingarna ...
(
- Contribution to journal › Article
-
Mark
Regimens of factor VIII administration--continuous infusion vs. bolus
(
- Contribution to journal › Article
-
Mark
Molecular genetic analysis of severe protein C deficiency
(
- Contribution to journal › Article
-
Mark
Recombinant FVIIa in the treatment of warfarin bleeding
(
- Contribution to journal › Article
-
Mark
Replik: Behandlingstiden har effekter och bieffekter
(
- Contribution to journal › Article
-
Mark
The Malmo model for immune tolerance induction: impact of previous treatment on outcome
(
- Contribution to journal › Article
- 1999
-
Mark
Tolerance induction using the Malmo treatment model 1982-1995
(
- Contribution to journal › Article
-
Mark
Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized
(
- Contribution to journal › Article
-
Mark
Progression of retinopathy after improved metabolic control in type 2 diabetic patients. Relation to IGF-1 and hemostatic variables
(
- Contribution to journal › Article
-
Mark
Centraliserad vård grundläggande i vårdprogram för blödarsjuka
(
- Contribution to journal › Article
-
Mark
Nya rön om behandling av djup ventrombos: Behandlingstidens längd föremål för internationella studier
(
- Contribution to journal › Article
-
Mark
Malmo International Brother Study (MIBS): an international survey of brother pairs with haemophilia
(
- Contribution to journal › Article